预约演示

更新于：2025-03-10

Cannabinoids

大麻素

更新于：2025-03-10

概要

基本信息

药物类型

小分子化药

别名

Cannabinoids、Orthocann、ReneCann

+ [9]

靶点

A3R

作用机制

A3R激动剂(腺苷A3受体激动剂)

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病遗传病与畸形+ [8]

在研适应症

膝关节炎特应性皮炎银屑病+ [13]

非在研适应症

葡萄球菌感染

原研机构

Can-Fite BioPharma Ltd.

在研机构

Andira Medicine, Inc.初创企业

Incannex Healthcare, Inc.

Avextra Pharma GmbH

+ [9]

非在研机构

NEVIS BRANDS, INC. /US/

Skye Bioscience, Inc.

University of Mississippi

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

项与大麻素相关的临床试验

ACTRN12622000419763

/ Not yet recruiting临床2期IIT

The CANnabinoids in CANcer (CANCAN) trial: Investigating the effect of medicinal cannabis on symptoms and side effects of chemotherapy in people with cancer

开始日期2025-02-01

申办/合作机构

Central Adelaide Local Health Network, Inc.

ChiCTR2400094082

/ SuspendedN/AIIT

Investigation of the clinical features of synthetic cannabinoid drug users

开始日期2025-01-01

申办/合作机构-

DRKS00034785

/ RecruitingN/AIIT

Experiences of patients with chronic non-tumor pain undergoing cannabinoid therapy - a qualitative analysis - CANQUAL

开始日期2024-09-11

申办/合作机构-

100 项与大麻素相关的临床结果

登录后查看更多信息

100 项与大麻素相关的转化医学

登录后查看更多信息

100 项与大麻素相关的专利（医药）

登录后查看更多信息

8,643

项与大麻素相关的文献（医药）

2025-12-01·Current gastroenterology reports

Selected Use of Complementary and Alternative Medicine (CAM) Agents in IBD

Review

作者: Schneider, Yecheskel ; Rollins, Samantha ; Dzwonkowski, Monica ; Bahirwani, Janak ; Muratore, Alicia ; Christian, Vikram

PURPOSE OF REVIEW:

Inflammatory bowel disease (IBD) can cause significant psychological, physical, and economic burdens on patients and healthcare systems. Studies show over one-fifth of patients will seek nontraditional methods of treatment for managing their symptoms. Understanding the benefits - and potential harms - of these therapies is important to provide holistic and evidence-based care to our IBD patients.

RECENT FINDINGS:

In this review, we present several studied herbal therapies for the management of both Crohn's disease and ulcerative colitis. These include cannabinoids, Tripterygium wilfordii, Chios mastic gum, Boswellia serrata, Indigo Naturalis, curcumin, resveratrol, and Zingiber officinale. While these herbal remedies have been shown to have anti-inflammatory effects and positive outcomes in IBD patients, larger scale studies are lacking and the use may be limited by bioavailability, lack of standardization of formulations, and adverse reactions. In reviewing the literature, we discuss the current data available including benefits, adverse reactions, and considerations for use surrounding several of the more common herbal remedies used for IBD.

2025-05-01·EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Cannabidiol—A friend or a foe?

Review

作者: Tihăuan, Bianca-Maria ; Gună, Daniel ; Onisei, Tatiana ; Slootweg, Walter ; Chifiriuc, Mariana-Carmen ; Iliescu, Ciprian

Cannabidiol (CBD), one of the main actives from Cannabis sativa has been perpetually explored lately for its therapeutic effects. Its main attributes, such as anti-inflammatory and antioxidant effects, snowball into pain management, epilepsy and seizure alleviation, anxiety relief, as well as numerous other implications through the entire metabolism. However, conventional administration routes challenge its therapeutic potential, with reported poor water solubility, hepatic degradation, gastric instability and erratic bioavailability observed in oral administration. As a result, the transdermal delivery systems have emerged as a promising alternative to oral or inhaled routes, offering improved bioavailability and targeted effects. The medical use of CBD throughout Europe, UK, USA or Australia is extensive and usually represented by pharmaceutical preparations recommended after conventional treatment routs fail. The non-medical use is limited by each country's own legislation, a wider range of products being available, but the irregular regulatory landscape coupled with the growing market of cannabinoid-infused products, emphasizes the need for standardized formulations and further clinical research. The present work critically examines the transdermal administration of cannabidiol, explores the skin's potential as a route and the strategies involved in using it for systemic targeting. We highlighted key challenges and provided insights into CBD`s variable bioavailability based on different administration routes and methods, thus compiling a literature-based absorption, distribution, metabolism, and excretion (ADME) study. We also explore the role of the endocannabinoid system, its function in various medical conditions, and the therapeutic effects associated with CBD, particularly in light of the varying legislation across countries. While the breadth of potential benefits is compelling, it is essential to emphasize the ongoing nature of CBD research as individual responses to it can vary significantly.

2025-05-01·Current Neuropharmacology

The Impact of Potent Addictive Substances on Angiogenic Behavior: A Comprehensive Review

Article

作者: Alahmad, Saif Zuhair ; Khair, Iliya Yacoub ; Al-Eitan, Laith Naser

Angiogenesis, the formation of new vasculature from preexisting vasculature, is involved in the development of several diseases as well as various physiological processes. Strict cooperation of proangiogenic and antiangiogenic factors mediates the control of angiogenesis. The fundamental steps in angiogenesis include endothelial cell proliferation, migration, and invasion. Addictive substances, which are considered therapeutic candidates in research and medicine, are classified as natural substances, such as nicotine, or synthetic substances, such as synthetic cannabinoids. Addictive substances have been shown to either enhance or suppress angiogenesis. This review article provides an overview of recent studies concerning the effects of several addictive substances on the process of angiogenesis. Google Scholar and PubMed were used to collect the scientific literature used in this review. The addictive substances addressed in this review are nicotine, opioids such as morphine and heroin, alcohol, cocaine, methamphetamine, and cannabinoids. An accurate assessment of the influence of these substances on the angiogenic process may help to construct a potentially effective therapeutic protocol to control and treat several angiogenesis-related diseases.

430

项与大麻素相关的新闻（医药）

2025-03-07

·抗体圈

一桩意外并购

前言：近日，一起突如其来的收并购点燃了美股投资者：Jazz Pharmaceuticals（Nasdaq:Jazz）和Chimerix（Nasdaq:CMRX）宣布两家公司已达成最终协议，Jazz将以每股8.55美元的现金收购Chimerix，总对价约为9.35亿美元。该交易已获得两家公司的批准，预计将于2025年第二季度完成。要知道，这场交易前一天的股价也不过5美元出头，也就是说，本次收购费用几乎翻了CMRX的一倍。CMRX的管线确实不算大众，但能让Jazz看上并溢价90%以上进行收购，必定有其独特的魅力。而收购之后的Jazz，又有哪些看点？ 01 CMRX的管线 CMRX的管线来看，目前能进行估值的管线只有一条——ONC201。该条管线目前也已经冲破重重艰难险阻就快修成正果，到了FDA上市审批（NDA）的阶段。这条管线从第一次开始临床试验（first man）到现在，已经历经10余载，从中也能看出小biotech从头走过来到被收购的完整历程。（图片来源：CMRX官网） ONC201靶向DRD2和ClpP，主要治疗的患者是患有携带H3K27M突变的复发型胶质瘤患者。众所周知，胶质瘤按照危险程度一共分为I-IV级，III级和IV级是高级别胶质瘤，当外科手术切除之后复发，目前非常缺乏治疗手段。当现治疗“癌王”胰腺癌的药物不断涌现进行临床患者招募，治疗高级别胶质瘤却处于一筹莫展的境况。该突变方面，在临床上，H3 K27M突变的肿瘤通常处于上文所说的IV级，预后较差。如图所示，在位于脑桥的胶质瘤中，携带这种突变的比率高达75%，而位于脑室的胶质瘤中，携带这种突变的比率也高达71%；此外，约10%的成人神经胶质瘤也显示H3 K27M突变。（图片来源：CMRX官网PPT）人数方面，全美国每年约有21000人被诊断为胶质瘤，其中大约有2000名患者受到H3 K27M突变的影响。市场的整体情况大致如此。而ONC21的机制方面，它的机制也确实非常非常有意思。它一方面可以激动ClpP（Clp蛋白酶蛋白水解亚基）。ClpP是胶质瘤中线粒体的蛋白酶，可以降解线粒体呼吸链蛋白以破坏能量稳态，而胶质瘤的繁殖自然需要大量的能量来进行支撑，因此，破坏能量稳态对影响其增殖起到了重要的作用。也正因为此，在治疗过程中，ClpP会作为重要的biomarker存在。另一方面，ONC21其实一开始被发现的机制并不是激动ClpP，而是拮抗多巴胺受体D2 (DRD2)，关于这条通路是怎样影响肿瘤的，目前尚不是很清楚，但DRD2是一种G蛋白偶联受体，它可以调节Ras通路；而RAS-RAF-MEK-ERK（简称ERK信号通路）是调控细胞增殖与存活的核心通路，其异常活化与多种癌症的发生发展密切相关。阻断上游Ras信号，对抑制肿瘤活化增殖，促进细胞凋亡也许有意想不到的作用。但具体ONC21通过DRD2是怎么抑制肿瘤，目前研究并不算很透彻。这大致是目前机制上的情况。目前能看到的是早期临床试验数据，总量人数为50人。在高级胶质瘤方面，ORR为20%，低级别胶质瘤方面，ORR为26%，以RNAO2.0评估的胶质瘤疗效标准方面，ORR为28%。该药很早就获得了快速通道资格和孤儿药认定，而目前已经走到了申报上市这一步，相信之后的东西，也会是水到渠成。 02 Jazz近况 Jazz作为一家pharma而言市值并不算很高，甚至没有单一管线的summit高，目前市值为84亿美元左右；它的成名来源与对大麻素的销售，是全球著名的大麻素销售巨头。其核心单品为Epidiolex，它是第一个也是唯一一个获得FDA 批准的处方大麻二酚 (CBD)，用于治疗1岁或以上患者与Lennox-Gastaut综合征(LGS)、Dravet综合征或结节性硬化症 (TSC)相关的癫痫发作。它来自于2021年一桩巨额收购案：Jazz以72亿美元收购GW pharma。其相关的大麻类药物还有satyivex。除此之外，其在2005年收购了Orphan Medical，拿到了羟基丁酸钠这款药物，用于治疗白天嗜睡。除了上述的精神类药物，Jazz在其它领域也有浓墨重彩的商业化布局。例如defitelio（去纤维钠）治疗肝窦阻塞综合征，RYLAZE治疗大肠杆菌衍生的天冬酰胺酶过敏的成人和1个月或以上的小儿患者的急性淋巴细胞白血病(ALL) 和淋巴母细胞淋巴瘤 (LBL)等。如图所示为Jazz的营收情况，2023年，其营收达到了38.34亿美元，总体而言，从现在Jazz的商业化版图来看，它的营收主要还是来自于精神类药物，尤其是大麻类药物，为此也产生过不少专利纠纷，除了精神类药物之类的商业化单品很杂，给人一种不太成体系的感觉。（图片来源：Jazz 2023年年报）然而从研发管线上来看，却可以看到Jazz拼尽全力向肿瘤领域转型的决心，如果不去看商业化板块，只去看管线，甚至会以为它是一家正在起步推进管线的肿瘤biotech。其中，其肿瘤的首发管线Zanidatamab在2024年底已经被FDA批准，进入了上市阶段。该管线是一条HER2双表位抗体，也是Jazz渴望转型的一个体现：2022年，Jazz从zymwok以5000万美元的一次性付款，3.75亿美元的预付款引进该管线，且总交易金额达到了17.6亿美元。目前，该BD算是有了初步结果，结出的第一个获批适应症二线治疗胆管癌，目前一线治疗胆管癌，一线治疗胃食管腺癌等也已经进入了三期临床阶段，二期临床还有乳腺癌等大适应症在持续推进。该单品的商业化进程预计将会波澜壮阔。除此之外，化疗药物芦比卡定也已经获得了批准上市，该药是Jazz通过从PharmaMar手中BD获得，目前用于治疗小细胞肺癌。JZP351则是一种化疗药物组合，目前在治疗白血病的III期临床阶段。可以看到，Jazz一边收购大麻巨头获得稳健的营收保障，一边不断进行肿瘤药物的BD，用于后续管线的布局，让公司看起来充满预期。 03 结语从上述对两家企业的叙述中，本次收购就显得合理了起来，Jazz渴望进一步充实肿瘤管线，它在拥有HER2双抗这项大分子肿瘤药物，已经几款化疗药物药物之后，选择了一家小分子biotech进行收购，一方面是让肿瘤管线看起来更加多元化，另一方面也确实是选择了剑走偏锋的差异化竞争。除此之外，后续管线的潜力也不容小觑：首当其冲的是后续管线ONC206，它是ONC201的下一代同靶点药物，体外活性是ONC201的10倍，拥有非常强劲的体外抗肿瘤活性，目前临床剂量递增试验已经完成。 ONC212和CMX521都在有序推进之中。总体来说这次收购是Jazz的一次为了扩张肿瘤板块而进行的又一次大动作，既在意料之外，又在情理之中。CMRX也提前上岸，是非常不错的biotech结局。识别微信二维码，添加抗体圈小编，符合条件者即可加入抗体圈微信群！请注明：姓名+研究方向！本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

并购临床3期

2025-02-24

·PRNewswire

Charlotte's Web Announces DeFloria to enter Phase 2 FDA Clinical Trial for Autism Spectrum Disorder Treatment

LOUISVILLE, Colo., Feb. 24, 2025 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. (" Charlotte's Web" or the " Company"), a market leader in hemp extract wellness products, is pleased to announce that the U.S. Food and Drug Administration (FDA) has completed its review of Phase 1 data and Investigational New Drug (IND) application submitted by DeFloria, Inc. ("DeFloria"). The FDA has concluded that DeFloria may now proceed with its planned FDA Phase 2 clinical trial for its botanical pharmaceutical candidate, AJA001 Oral Solution, a treatment for symptoms of autism spectrum disorder (ASD). "Progressing to Phase 2 of an IND study with the FDA marks an important milestone in the development of our proprietary hemp genetics as regulated medicine," said Bill Morachnick, Chief Executive Officer of Charlotte's Web. "By leveraging our deep expertise in hemp cultivation and proprietary formulations, we are reinforcing and extending our leadership in hemp wellness from the consumer sector into the regulated medical sector. A safe and effective botanical treatment for autism spectrum disorder would be a medical asset that could provide immense value to millions of families and Charlotte's Web." DeFloria is a collaboration including Charlotte's Web and Ajna BioSciences PBC, a botanical drug development company, to develop AJA001 as a treatment for irritability associated with autism spectrum disorder. AJA001 employs Charlotte's Web proprietary full-spectrum cannabidiol (CBD) hemp extract derived from one of its patented cultivars. Drawing on a decade of research, innovation, and rigorous cultivation methods from Charlotte's Web, DeFloria is developing AJA001 with the Company's proprietary hemp genetics as the foundation of the botanical drug. "Advancing AJA001 to Phase 2 is a landmark moment for botanical drug development," stated Dr. Marcel Bonn-Miller, Chief Scientific Officer at Charlotte's Web and DeFloria Board Member. "Charlotte's Web has aimed to meet the needs of those underserved by current therapies for the past decade. AJA001's journey through the FDA's botanical drug pathway showcases the wide therapeutical potential of hemp. We feel this research strongly supports cannabinoids as a viable therapy for irritability associated with autism spectrum disorder, which currently lacks adequate treatment options. DeFloria is at the cutting edge with AJA001, and we are eager for DeFloria to begin Phase 2 of development." DeFloria's planned Phase 2 clinical trial will evaluate the safety, tolerability, and effectiveness of AJA001 among adolescents and adults with ASD, building on the promising results from Phase 1. Data from Phase 2 studies will be used to inform the design of larger Phase 3 clinical trials, the results from which will be submitted to FDA for drug approval. For more information see today's announcement from DeFloria: Subscribe to Charlotte's Web investor news. About Charlotte's Web Holdings, Inc. Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in Louisville, Colorado, is the market leader in innovative hemp extract wellness products that include Charlotte's Web whole-plant full-spectrum CBD extracts as well as broad-spectrum CBD certified NSF for Sport®. Charlotte's Web branded premium quality products start with proprietary hemp genetics that are North American farm-grown using organic and regenerative cultivation practices. The Company's hemp extracts have naturally occurring botanical compounds including cannabidiol ("CBD"), CBN, CBC, CBG, terpenes, flavonoids, and other beneficial compounds. Charlotte's Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, calming, exercise recovery, immunity), CBN gummies, functional mushroom gummies, CBD capsules, CBD topical creams, and lotions, as well as CBD pet products for dogs. Through its substantially vertically integrated business model, Charlotte's Web maintains stringent control over product quality and consistency with analytic testing from soil to shelf for quality assurance. Charlotte's Web products are distributed to retailers and healthcare practitioners throughout the U.S.A. and online through the Company's website at . Charlotte's Web is the official CBD of Major League Baseball©. © Major League Baseball trademarks and copyrights are used with permission of Major League Baseball. Visit MLB.com. Forward-Looking Information Certain information provided herein constitutes forward-looking statements or information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Forward-looking statements are typically identified by words such as "may", "will", "should", "could", "anticipate", "expect", "project", "estimate", "forecast", "plan", "intend", "target", "believe" and similar words suggesting future outcomes or statements regarding an outlook. Forward-looking statements are not guarantees of future performance and readers are cautioned against placing undue reliance on forward-looking statements. This press release includes forward-looking statements including: the future performance or achievements of DeFloria, Inc., future dose trial results, therapeutic efficacy, or approvals of AJA001 Oral Solution the results of which may be materially different from those expressed or implied by the forward-looking statements contained in this press release. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties, and other factors which may cause actual results, levels of activity, and achievements to differ materially from those expressed or implied by such statements. The forward-looking statements contained in this press release are based on certain assumptions and analysis by management of the Company in light of its experience and perception of historical trends, current conditions and expected future development and other factors that it believes are appropriate and reasonable. The material factors and assumptions used to develop other forward-looking information herein include factors discussed throughout the "Risk Factors" section of the Company's most recently filed annual information form available on and in the Company's most recently filed Annual Report on Form 10-K and quarterly report on Form 10-Q as amended, and other filings with the Securities and Exchange Commission available on . Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. SOURCE Charlotte's Web Holdings, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期

2025-02-24

·CPHI制药在线

大麻二酚的药理研究进展

关注并星标CPHI制药在线植物大麻是最早被人类认识的成瘾物质之一，同时也有不可忽视的医疗潜力。大麻素是大麻发挥药理活性的主要成分，随着大麻活性成分的提纯以及内源性大麻素递质系统的发现，大麻素因其广泛的生理作用及潜在的临床应用价值日益受到重视。目前从植物中分离并鉴定出的大麻素以Δ9-四氢大麻酚(Δ9-Tetrahy drocannabinol, Δ9-THC)和大麻二酚（CBD）为主。Δ9-THC是大麻植物的主要精神活性成分，虽然具有有益的镇痛、抗炎和抗癫痫等作用，但其“高”精神活性导致的严重不良反应，如成瘾、认知障碍、运动不协调、焦虑等限制了它在临床的应用。CBD是大麻植物中主要的非精神活性成分，具有镇痛、抗炎、神经保护和抗精神病等作用，且不会产生典型的大麻素副作用，即具有非成瘾性，在人类以及动物体内有良好的耐受性；不影响人体运动、记忆等。因此，作为一种耐受性好、安全的天然化合物，CBD成为一个具有吸引力和临床应用前景的药物。 CBD是一种脂溶性多靶点药物，包括大麻素受体(Cannabinoid Receptor,CBR)、5-羟色胺1A 受体、瞬时受体电位受体1、腺苷和甘氨酸受体等。体内研究表明，CBD 对大麻素受体的亲和力比较低，而对5-羟色胺受体(5-Hydroxytryptamine Receptor, 5-HTR)、非内源性大麻素G蛋白偶联受体以及酶和某些离子通道等靶标具有更强的亲和力，对神经疾病包括焦虑、精神分裂症、成瘾、神经退行性疾病和新生儿低氧缺血性脑病均具有明显的改善作用。另外，在抗癫痫、抗肿瘤、抗炎、肝保护、糖尿病、疼痛的治疗上也表现出很好的应用前景。 1、大麻二酚与神经性疾病大麻二酚具有广泛的生物效应，在神经系统中有多种潜在的作用部位，被评估为一种治疗神经疾病的药物。对焦虑、精神分裂症、成瘾、神经退行性疾病、缺氧缺血脑病等都有一定的效果。 ①抗焦虑作用与大麻二酚抗焦虑作用相关的受体有CB1 受体、TRPV1 受体和5-HT1A 受体。CBD 对CB1受体的亲和力较低，但它作为一种间接激动剂发挥作用。CBD 在高浓度时充当TRPV1 激动剂，可能通过干扰花生四烯乙醇胺的失活来发挥作用。5-HT1A受体是目前已确定的抗焦虑靶点。动物试验表明，低剂量的大麻二酚通过激动5-HT1A 受体，来发挥抗焦虑作用；过量的大麻二酚则会激活TRPV1 受体，增加焦虑。另外，试验还发现大麻二酚可以使人产生抗焦虑作用，可以用来治疗社交焦虑障碍。 ②抗精神分裂症抗精神病药物通过拮抗中枢多巴胺D2 受体发挥作用，虽然它们对大多数患者有效，但多达三分之一的患者治疗效果不佳。然而CBD 并不依赖于多巴胺D2 受体的拮抗，而是通过抑制脂肪酸酰胺水解酶、抑制腺苷酸再摄取、激动TRPV1 和5-HT1A 受体来发挥作用。研究发现CBD 可以改善对氟哌啶醇没有效果的病人的症状。研究报道额纹状体偶联下降是精神分裂症的中间表型，而CBD 导致额纹状体连接增加，提示CBD在精神分裂症患者中潜在的治疗用途。将CBD 作为辅助药物，加入到抗精神病的治疗中与对照组相比，产生了更好的治疗效果。患者的认知功能和整体功能水平有所提高，运动速度和行动能力的改善效果最为显著。但每组中有三分之一的患者出现了不良反应，例如血脂异常和恶心，不过副反应的症状大部分是轻微的，可自行解决，表明CBD 具有良好的耐受性。 ③抗成瘾性研究大麻使用者成瘾性结果发现，单独使用THC 或二者合用均会造成精神损伤，而只使用CBD 则无精神损伤作用，且CBD 能改善低频率大麻使用者的精神症状，对高频率大麻使用者无效。评估40 名大麻依赖者对服用Nabiximols (27 mg/mL THC/25 mg/mL CBD)的耐受性和安全性。研究发现，Nabiximols有助于减少大麻的使用量，而不增加患者对大麻的渴望。此外，CBD也有利于烟草的戒断。 ④抗神经退行性疾病大脑中铁的积累被认为是正常衰老的特征。然而，在阿尔茨海默氏症(AD)、帕金森症(PD)和亨廷顿氏症(HD)等神经系统疾病中，铁选择性地聚集在与相关的神经退行性过程有关的大脑区域，如海马、黑质、皮质和基底神经节。研究发现CBD 可以通过阻断铁诱导的细胞凋亡，来发挥神经保护作用，使得CBD 成为一种潜在的治疗神经退行性疾病的药物。此外，β-淀粉样肽聚集和微神经胶质细胞的激活与AD的发生联系紧密。CBD可通过Wnt/β-catenin信号转导通路抑制tau蛋白的高度磷酸化，从而避免β-淀粉样肽聚集所产生的毒害或通过阻止由β-淀粉样肽诱导的微神经胶质细胞的激活，实现对脑神经元的保护。CBD可通过神经元蛋白和trkA (神经生长因子受体）介导抑制与PD密切相关的神经毒物质MPP + (1-甲基-4-苯基-1,2,3,6-四氢吡啶）的作用，而MPP +可导致神经元细胞的死亡和神经突触的缺失。 ⑤抗新生儿低氧缺血性脑病 CBD对急性缺氧缺血后的神经具有保护作用，因此能够治疗新生儿缺氧缺血脑病。CBD 能够阻止钙的增加，减少谷氨酸的释放和NO 产生，抑制细胞核因子-κB (NF-κB)的转录活性，具有抗氧化结构及扩张血管的特点，具有神经胶质保护作用。CBD 能保护婴儿的大脑，不仅具有控制兴奋性、炎症和氧化应激的神经调节作用，还能减弱神经退化和有害神经胶质的激活。 2、大麻二酚与癫痫病 CBD对难治性癫痫具有一定的抑制效果，且能减少癫痫的发作频次。CBD能有效地减少Dravet 综合征模型小鼠的癫痫发作频率，但同时发现，癫痫发作次数减少了，生活质量提高了，CBD 的不良反应发生率也会增高，常见的不良事件包括嗜睡、厌食和腹泻。采用CBD治疗顽固性癫痫Sturge-Weber 综合症，所有受试者在CBD 治疗的大部分时间里生活质量改善了，其轻微的副作用可以被人体很好的耐受。目前，英国GW制药公司研制的Epidiolex(主要成分为CBD)和 Sativex(THC/CBD比值为1)这两种药物已在欧美市场销售，前者主要用于治疗婴儿严重肌阵挛性癫痫(Dravet)和儿童期弥漫性慢棘-慢波（小发作变异型）癫痫性脑病（Lennox-Gastaut)，后者主要治疗多发性硬化症。 3、大麻二酚与抗肿瘤作用 CBD对多种肿瘤细胞具有抑制作用，其抗肿瘤作用根据癌症组织类型不同，其作用机制各不相同。CBD对神经胶质瘤、白血病和前列腺癌具有一定的抑制作用。无血清条件下，CBD和他莫昔芬(tamoxifen,抗雌激素）与C6神经胶质瘤细胞共同孵化，对神经胶质瘤表现出一定的抑制作用。CBD通过半胱天冬酶的激活和活性氧的参与等机制诱导人类神经胶质瘤细胞U87和U373的凋亡。CBD通过对NOX4和P22phox的调控导致活性氧簇（ROS )的增加而实现对EL-4、Jurkat白血病细胞的抑制。CBD同样可阻滞前列腺癌细胞的增殖或诱导其凋亡。此外，CBD可通过调控AKT/mTOR/4EBPl、EGF/EGFR信号途径或通过诱导内质网激压力抑制乳腺癌细胞的生长和转移。 4、大麻二酚与代谢和免疫调节作用 CBD可通过调控炎性因子水平、控制干扰素的产生等起到代谢和免疫调节作用。CBD对糖尿病的发生或是早期糖尿病的治疗均有一定的控制效果。一方面，CBD可通过抑制胰腺炎的发生和炎性Th-1相关细胞因子的产生，将免疫反应从Th-1 (炎症性细胞因子占优势）模式转向Th-2 (抗炎症性细胞因子占优势)模式，从而降低糖尿病的发生几率，另一方面，针对早期糖尿病，CBD处理可大大降低促炎性因子IL-12水平，而抗炎性因子IL-10水平则显著升高，且胰岛组织学检查结果也优于对照组。研究发现CBD 能够降低非肥胖型糖尿病小鼠的发病率，这种效应与减少的胰岛炎结合在一起，导致促炎细胞因子的水平降低。CBD 能够减少与糖尿病相关的氧化应激、炎症、细胞死亡和血管通透性。CBD 通过G蛋白偶联受体18 (GPR18)依赖性地恢复心脏的脂联素-蛋白激酶B-内皮型一氧化氮合酶(adiponectin-Akt-Enos)信号和减少心肌氧化应激，来减轻糖尿病诱发的心血管异常。此外，CBD 对糖病引发的抑郁也可以产生轻微的抑制作用。因此CBD 能够改善糖尿病及其并发症。此外，经CBD处理后的小鼠引流区淋巴结细胞的II型胶原特异性扩增水平和γ干扰素水平明显降低，滑膜细胞释放的a干扰素也相应减少，结果表明腹腔注射或口服CBD均能有效阻止关节炎的发展。 5、大麻二酚与肝保护功能 CBD可以减轻肝脏损伤，降低肝脏甘油三酯的水平，还可在细胞水平减轻油酸所致人肝脏细胞脂肪堆积，具有肝保护功能。CBD 可通过诱导脂解或增强线粒体活性来抑制脂肪肝，还可以改善胰岛素敏感性，这两种化合物可被用作治疗肥胖症和代谢综合征相关肝病。CBD可以通过降低醇介导的氧化应激，抑制JNK MAPK通路的激活和增加自噬等多种机制保护小鼠肝脏免受酒精诱导的脂肪变性。此外，CBD对于缺血性肝损伤和慢性酒精中毒引起的肝损伤也有一定的保护作用。在小鼠发生缺血性肝损伤一小时后经尾静脉注射5 mg/kg/天 CBD，两天后发现，对照组中出现了由缺血引起的一系列生化指标的升高，如血清丙氨酸氨基转移酶、肝组织丙二醛、TNF-a (肿瘤坏死因子-a )和一氧化氮水平等，而CBD组无上述现象，提示CBD可能可用于解决肝移植手术因短暂性缺血导致的肝组织损伤难题。CBD对慢性酒精中毒引起的肝损伤也有一定的保护作用，如CBD可减轻由长期的酒精刺激所导致的肝损伤（包括肝转氨酶水平的升高、甘油三酯和中性粒细胞的积累及炎性因子的表达等）。参考资料: [1]郭蓉,陈璇,郭鸿彦.四氢大麻酚和大麻二酚的药理研究进展[J].天然产物研究与开发, 2017, 029(008):1449-1453. [2]韩莎莎,张殿杭,李丽.大麻二酚的药理研究进展[J].药物资讯, 2019, 8(3):7. 作者简介：小米虫，药品质量研究工作者，长期致力于药品质量研究及药品分析方法验证工作，现就职于国内某大型药物研发公司，从事药品检验分析及分析方法验证。智药研习社近期直播预告扫码领取CPHI & PMEC China 2025展会门票来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

100 项与大麻素相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床1期	美国	Cannabis Bioscience International Holdings, Inc.	2024-03-20
特应性皮炎	临床阶段不明	荷兰	Incannex Healthcare, Inc.	2023-04-17
银屑病	临床阶段不明	荷兰	Incannex Healthcare, Inc.	2023-04-17
白癜风	临床阶段不明	荷兰	Incannex Healthcare, Inc.	2023-04-17
阿尔茨海默症	临床申请批准	意大利	Avextra Pharma GmbH	2024-10-08
肌萎缩侧索硬化	临床申请批准	意大利	Avextra Pharma GmbH	2024-10-08
帕金森病	临床申请批准	意大利	Avextra Pharma GmbH	2024-10-08
癌症疼痛	临床前	加拿大	Andira Medicine, Inc.初创企业	2025-01-21
脑癌	临床前	澳大利亚	Zelira Therapeutics Ltd.	2024-09-24
脑癌	临床前	澳大利亚	Telethon Kids Institute	2024-09-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CRD42023479375 (ESMO2024)	N/A	癌症疼痛	-	Cannabinoids	簾製襯窪繭鬱繭願鑰獵(繭壓願築醖衊醖廠簾蓋) = 鹽獵積網鏇壓窪壓鏇遞夢夢觸構製醖壓糧夢範 (顧鹹醖壓醖網憲範繭衊, -0.65 ~ 0.75) 更多	积极	2024-09-15
EAN2024	N/A	新生儿窒息	-	URB447 + TH	構積構鏇獵顧艱繭鹽夢(獵齋糧築顧範艱壓網艱) = 鑰膚願壓廠醖鬱衊積壓積淵積餘遞蓋窪艱構範 (遞遞憲憲觸艱築構願遞 ) 更多	-	2024-06-28
				TH + URB447	構積構鏇獵顧艱繭鹽夢(獵齋糧築顧範艱壓網艱) = 築選簾築鏇廠糧簾憲窪積淵積餘遞蓋窪艱構範 (遞遞憲憲觸艱築構願遞 ) 更多
NCT03782402 (CTgov)	临床2期	周围神经系统疾病	12	Cannabinoids (Placebo Cannabinoids)	築糧製構憲鏇鬱糧顧壓(鹽憲壓夢壓觸夢襯壓構) = 願簾鏇構遞憲願積遞範餘網觸簾鏇襯憲鹹遞顧 (選蓋窪憲衊範鑰鹹齋鏇, 網壓糧齋顧襯顧鹹衊鹽 ~ 顧糧窪艱餘網網選繭鹽) 更多	-	2023-01-26
				Cannabinoids (Cannabinoids (THC and CBD))	鏇夢範膚醖夢願艱構選(醖膚構網窪廠壓簾構積) = 網襯糧網遞範蓋糧壓蓋廠簾鏇鏇鬱構鏇選願選 (遞遞醖壓鏇網鬱夢網遞, 廠蓋獵製築齋構範衊選 ~ 糧艱築獵齋餘製鏇餘艱) 更多
EULAR2022	N/A	银屑病关节炎	-	Cannabinoid (Rheumatoid Arthritis patients using cannabis)	淵窪觸積齋鏇糧繭構憲(構簾鑰鹹顧窪鹽艱選艱) = 17.5% of patients with RA using cannabinoids reported side effects not leading to cessation 遞製築蓋夢網網襯鏇壓 (築製鏇鬱憲鏇憲積築糧 )	-	2022-06-01
ISC2022	N/A	缺血性卒中 cannabinoid positive	256	Cannabinoid positive	餘夢淵簾網選選淵壓遞(壓襯獵夢淵構夢遞構夢) = 顧觸憲網醖選選淵網鬱鹽窪憲淵鏇顧選鹹簾鹹 (蓋製襯網鏇憲鏇淵鹹淵 )	-	2022-02-01
				Cannabinoid negative	餘夢淵簾網選選淵壓遞(壓襯獵夢淵構夢遞構夢) = 顧繭夢衊廠廠餘選膚糧鹽窪憲淵鏇顧選鹹簾鹹 (蓋製襯網鏇憲鏇淵鹹淵 )
ASN2020	N/A	急性肾小管坏死	-	Synthetic cannabinoids (SC)	齋製製繭積願鹽餘鬱壓(壓鑰壓願窪願鹽鹽構築) = A renal biopsy showed acute tubular injury with tubular dilatation, cytoplasmic simplification and vacuolization (image) 壓淵艱鏇繭鬱糧窪膚顧 (繭淵築齋餘觸製獵鏇鏇 ) 更多	-	2020-10-19
SNMMI2020	N/A	功能障碍	-	Regular users of legal marijuana	鑰獵範願淵餘膚構願襯(築願鑰餘膚鹽築願夢製) = 窪衊艱艱製網齋簾艱鏇鏇膚鹹壓觸壓鬱築鬱鏇 (艱艱襯選鹽構簾憲築鹽 )	-	2020-05-15
SFN2017	N/A	认知功能障碍	-	N-Methyl-Pyrulol(NMP)	淵簾醖獵窪窪簾襯顧糧(獵醖觸範餘蓋範淵構製) = significant change in the learning process 構餘夢鏇願艱製窪襯衊 (繭蓋繭淵淵鹽壓憲築襯 ) 更多	-	2017-11-12
EAN2017	N/A	丛集性头痛 \| 偏头痛	-	THC+CBD 200 mg/day	壓鹽淵鏇願醖遞鏇範積(繭願選繭艱窪範築糧淵) = 顧糧鹹醖製廠簾築襯願鹹鑰齋鑰選鏇簾願鏇齋 (願範蓋製廠蓋廠願選製 ) 更多	积极	2017-07-13
				Amitriptyline 25mg/day	憲範網壓築築艱膚範壓(廠顧齋艱膚觸網顧築膚) = 襯膚鹽積淵蓋願積願獵蓋膚鹽鹹壓顧構鬱鹹繭 (糧廠鹹簾網艱簾鏇窪選 ) 更多
ISRCTN62942668 (CUPID, Pubmed \| Health Technol Assess)	临床3期	脑疾病 \| 多发性硬化症	498	Δ(9)-tetrahydrocannabinol (Δ(9)-THC)	齋網鑰糧製艱淵齋窪壓(網蓋鑰範餘憲範蓋遞製): hazard ratio = 0.92 (95% CI, 0.68 ~ 1.23)	-	2015-02-01
				Placebo